All Blogs
May 29, 2026
Cracks in the mCRPC Treatment Market: 8 Companies at Risk of Falling Behind
Summary The mCRPC market, valued at around USD 8 billion in 2025, is undergoing rapid disruption driven by scientific innovation, patent expirations, and shifting treatment paradigms. Once dominated by blockbuster androgen receptor inhibitors like ZYTIGA and XTANDI, the landscape is now fragmenting under pre...
Read More...
May 28, 2026
FDA Grants Breakthrough Device Status to TOBY’s Urine Test for Alzheimer’s Detection; ubtle Medical Achieves FDA Clearance for Next-Gen SubtleHD™(PET) Software; Ernest Health Expands Rehabilitation Network Through Reunion Hospitals Deal; Olympus Expands Prostate Cancer Footprint Through BioProtect Acquisition; ABILITY Neurotech Secures IMDD Approval for Clinical Trial of Chronic Brain-Computer Interface Implantation in ALS Patients; Implantica Reports Strong Economic Benefits of RefluxStop® in Italian GERD Treatment Study
TOBY Received FDA Breakthrough Device Designation for Its Urine-Based Alzheimer's Disease Diagnostic Test On 26 May 2026, TOBY, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device Designation to the TOBY Test for Alzheimer’s Disease. The designation recognized th...
Read More...
May 27, 2026
Cell and Gene Therapy Manufacturing: Engineering the Future of Medicine
Once confined to the realm of theoretical science fiction, cell and gene therapies (CGTs) have crossed decisively into clinical and commercial reality. In less than a decade, the world has witnessed landmark approvals, from the first CAR-T cell therapies for blood cancers to gene therapies restoring vision in patie...
Read More...
May 26, 2026
US Greenlight for Datroway Marks First TROP2 ADC Approval in Frontline mTNBC Beyond PD-1/PD-L1 Candidates; Gilead’s Hepcludex Achieves Historic FDA Approval Milestone in Chronic HDV; Biogen and Denali Therapeutics Report Progress in Phase 2b Evaluation of BIIB122 for Parkinson’s Disease; Eli Lilly and Company Spotlights Foundayo’s Late-Stage Success in Obesity Studies; BioMarin Shares Successful Phase 3 Study Outcomes for VOXZOGO® in Children with Hypochondroplasia
US Approves Datroway as the First TROP2-directed ADC for 1L mTNBC Patients Unsuitable for PD-1/PD-L1 Therapy AstraZeneca and Daiichi Sankyo have secured US approval for Datroway for treating adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor th...
Read More...
May 25, 2026
BeOne Enters the BCL-2 Arena: Can BEQALZI Disrupt VENCLEXTA’s Longstanding Dominance?
Summary BeOne Medicines received accelerated approval for sonrotoclax (BEQALZI) to treat adults with relapsed or refractory mantle cell lymphoma (MCL) who have failed at least two prior therapies, including a BTK inhibitor. Backed by Phase 1/2 trial data in 103 heavily pre-treated patients, the drug distingu...
Read More...
May 21, 2026
Leo Cancer Care Receives CE Mark Approval for Marie® Upright Radiotherapy System; PorTal Access, Inc. Hits Critical Regulatory Benchmark with Flexi-Port™ 510(k) Submission; Araceli Biosciences Introduces Endeavor® Live Cell to Accelerate AI-Driven Drug Discovery Imaging; TrilliumBiO Partners with Oncobit to Launch Next-Generation Uveal Melanoma Monitoring Platform; Advita Ortho Reports First Clinical Application of Equinoxe® Scapula Reconstruction System; Implantica Announces Findings Supporting RefluxStop®’s Economic Advantage in GERD Treatment in Italy
Leo Cancer Care Secured CE Mark for Marie®, Advancing Upright Radiotherapy in Europe On 21 May 2026, Leo Cancer Care announced that its flagship upright radiotherapy system, Marie, had received CE marking approval, enabling commercial deployment across Europe. The approval marked a significant advancement ...
Read More...
May 20, 2026
Plasmid DNA Manufacturing: The Backbone of Next-Generation Therapies
Plasmid DNA has moved from being a specialized laboratory tool to becoming one of the most strategic raw materials in modern biopharmaceutical manufacturing. In simple terms, a plasmid is a small, circular DNA molecule that exists separately from chromosomal DNA and can replicate independently inside microbial host...
Read More...
May 19, 2026
BAXFENDY Receives US Approval for Adult Hypertension as a First-in-Class Aldosterone Synthase Inhibitor; Regeneron Pharmaceuticals Shares New Developments in Phase 3 Melanoma Study of Fianlimab Combination; ENHERTU Gains Two New US Indications in HER2-positive Early Breast Cancer; REGENXBIO Reveals Positive Pivotal Trial Results for Duchenne Gene Therapy RGX-202; BeOne Medicines Gains FDA Approval for BEQALZI™ in R/R Mantle Cell Lymphoma
BAXFENDY Becomes the First FDA-Approved Aldosterone Synthase Inhibitor for Adults With Hypertension AstraZeneca’s BAXFENDY (baxdrostat) has received US approval as the first aldosterone synthase inhibitor (ASI) for treating hypertension in adults whose blood pressure remains uncontrolled despite the use of other...
Read More...
May 18, 2026
7 Therapies That Could Finally Change the Odds in Multiple Myeloma Treatment
Summary Multiple myeloma remains one of oncology's most challenging blood cancers, but the treatment landscape is undergoing a seismic shift. With the multiple myeloma market valued at USD 28.7 billion in 2025 and projected to grow steadily through 2036, the pipeline has never been more robust or more conse...
Read More...
May 14, 2026
Aurie Wins FDA De Novo Grant for Innovative Reusable Urinary Catheter Technology; Biozen Secures FDA Clearance for Calibration-Free Cuffless Blood Pressure Technology; plusOne® Expands Wellness Care Portfolio with New Menopause and Fertility-Friendly Lubricants; TrilliumBiO and Oncobit Introduce Advanced Uveal Melanoma Monitoring Solution in the U.S.; Renerva Announces First-in-Human Implant of PNM-CAP™ for Neuroma Pain; SonoClear AS Announces Completion of Clinical Enrollment for Breakthrough Device-Designated SonoClear® System
Aurie Received FDA De Novo Grant for First Automated Safely Reusable Intermittent Urinary Catheter System On 11 May 2026, Aurie announced that its Aurie Reusable No-Touch Intermittent Catheter System™ had received marketing authorization from the U.S. Food and Drug Administration (FDA) through the Class II De No...
Read More...